| SC 13G | 2019-06-10 | GILDER GAGNON HOWE & CO LLC | Magenta Therapeutics, Inc. | 4,175,181 | 10.6% | EDGAR |
| SC 13G/A | 2019-02-14 | Casdin Capital, LLC | Magenta Therapeutics, Inc. | 2,643,318 | 8.0% | EDGAR |
| SC 13G | 2019-02-13 | Atlas Venture Fund X, L.P. | Magenta Therapeutics, Inc. | 4,843,625 | 14.6% | EDGAR |
| SC 13G | 2019-02-13 | Third Rock Ventures GP IV, L.P. | Magenta Therapeutics, Inc. | 8,008,204 | 24.2% | EDGAR |
| SC 13G | 2019-02-13 | EVENTIDE ASSET MANAGEMENT, LLC | Magenta Therapeutics, Inc. | 2,650,808 | 8.0% | EDGAR |
| SC 13G | 2019-02-12 | GV 2016, L.P. | Magenta Therapeutics, Inc. | 3,339,137 | 10.1% | EDGAR |
| SC 13G | 2018-07-02 | Casdin Capital, LLC | Magenta Therapeutics, Inc. | 2,035,818 | 5.9% | EDGAR |